Simplify Logo

Internship

Simoa Software Intern

Onsite, Billerica, MA

Posted on 11/2/2023

Quanterix

Quanterix

201-500 employees

Ultra-sensitive biomarker detection technology

Data & Analytics
Consulting
Hardware
Biotechnology
Healthcare

Billerica, MA, USA

Category
Software Engineering
Required Skills
gRPC
Microsoft Azure
Python
Software Testing
Git
Data Structures & Algorithms
TypeScript
Requirements
  • Enrolled in or a recent graduate of a BS degree program in physics, mathematics, computer science, or equivalent (those enrolled in an MS or PhD program will also be considered)
  • Experience with C++, Python, C#
  • Solid understanding of algorithms and data structure
  • Experience with standard development tools: Azure, Git, CMake, visual studio/vscode
  • Experience with unit test framework (e.g., Google Test)
  • Excellent collaboration and communication capabilities
  • Ability to work well within cross-functional teams as a team player
Responsibilities
  • Develop the computation engine for the next generation Simoa technology
  • Design, develop, test, and deploy fully working software modules
  • Collaborate with software development team to build software infrastructure
  • Interface with engineers and assay scientists to optimize analysis software
  • Participate in Quanterix software code development and design reviews
Desired Qualifications
  • Experience with gRPC is a plus
  • Experience with TypeScript is a plus

Quanterix focuses on ultra-sensitive biomarker detection for early disease detection and monitoring in biotechnology and healthcare. Their key technology, Simoa (Single Molecule Array), allows for the detection of biomarkers at very low levels, which is crucial for identifying diseases before symptoms appear. Quanterix stands out by enhancing the sensitivity and specificity of biomarker detection, providing valuable tools for pharmaceutical companies, research institutions, and clinical labs. The company's goal is to empower early disease detection, ultimately improving patient outcomes.

Company Stage

IPO

Total Funding

$559.6M

Headquarters

Lexington, Kentucky

Founded

2007

Growth & Insights
Headcount

6 month growth

7%

1 year growth

13%

2 year growth

13%
Simplify Jobs

Simplify's Take

What believers are saying

  • The FDA's Breakthrough Device designation for Quanterix's p-Tau 217 blood test highlights its potential to revolutionize Alzheimer's disease diagnosis.
  • Partnerships with leading health networks like Mayo Clinic and Mass General Brigham expand Quanterix's reach and impact in clinical diagnostics.
  • Continuous innovation, such as the introduction of the Simoa Advantage PLUS platform, ensures Quanterix remains at the forefront of biomarker research.

What critics are saying

  • The highly competitive biotechnology sector requires Quanterix to continuously innovate to maintain its market position.
  • Dependence on partnerships and collaborations may pose risks if these relationships falter or fail to deliver expected outcomes.

What makes Quanterix unique

  • Quanterix's Simoa technology allows for ultra-sensitive biomarker detection, setting it apart from competitors in early disease detection.
  • The company's focus on non-invasive blood-based biomarker tests for diseases like Alzheimer's provides a significant advantage over traditional, more invasive methods.
  • Quanterix's extensive patent portfolio, including over thirty U.S. patents, underscores its innovative edge in the biotechnology and healthcare markets.
INACTIVE